ReviewPubMed ID: 24638246·2014

Illegal melanotan II products: purity analysis and contamination screening

Cohen PA, Travis JC, Venhuis BJ.

JAMA Internal Medicine, 2014

Key finding

Only 35% of products met purity standards; 65% contained bacterial endotoxins or undeclared active ingredients; significant batch-to-batch variability.

Summary

Analysis of 17 seized and commercial melanotan II preparations, documenting purity, contamination, and consistency issues in illicit products.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

More research on Melanotan II